Anti-IL-33 monoclonal antibody Treatment of COPD and asthma Treatment of atopic dermatitis Treatment of diabetic kidney disease

Interleukin (IL)-33, a cytokine belonging to the IL-1 super-family, is believed to serve as an "alarmin." It interacts with the widely expressed receptors ST2 and IL-1 receptor acces-sory protein (IL-1RAP) to modulate its biological actions. Innate immune cells and Th2 cells are substantially induced to produce Th2 cytokines by IL-33, which may contribute to asthma and atopic dermatitis and the pathogenesis of chronic obstructive pulmonary disease, especially airway inflammation. Tozorakimab (MEDI-3506) is a human IgG1 monoclonal antibody (MAb) that prevents IL-33 signaling. More information on this MAb is needed, but early data indi-cate that it is well tolerated without safety concerns and can target the intended goals, at least in serum. These results support further investigation of the efficacy and safety of tozorakimab in COPD, asthma and other inflammatory dis-eases. An extensive program of clinical studies is, in fact, in progress.